Valneva (VALN) Q2 2026 Earnings Call Transcript
Motley Fool·
- Valneva reported half year 2026 product sales of €64 million and reaffirmed its full-year product sales guidance of €135 million to €150 million.
- The company posted a net loss of €63.3 million, impacted by non-recurring items including €9.7 million in IXCHIQ cancellation fees and a €4.5 million inventory impairment.
- Partner Pfizer filed a regulatory application for their partnered Lyme disease vaccine candidate with the European Medicines Agency, with regulatory decisions anticipated within the next 12 months.